ArticleBritish journal of pharmacology2003
Investigation of postjunctional alpha1- and alpha2-adrenoceptor subtypes in vas deferens from wild-type and alpha(2A/D)-adrenoceptor knockout mice.
Article in British journal of pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Flow-driven lumen remodeling and valve opening in the vas deferens.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Butylidenephthalide facilitates contractions via nonspecific binding to receptors in isolated guinea-pig vas deferens.Pharmaceutical biology · 2019Article
- Mechanisms of butylidenephthalide for twitch facilitation in electrically stimulated mouse vas deferens.Pharmaceutical biology · 2018Article
- Yohimbine is a 5-HT1A agonist in rats in doses exceeding 1 mg/kg.Neuroscience letters · 2015Article
- Effect of noni (Morinda citrifolia Linn.) fruit and its bioactive principles scopoletin and rutin on rat vas deferens contractility: an ex vivo study.TheScientificWorldJournal · 2014Article
- Physiological and pharmacological aspects of the vas deferens-an update.Frontiers in pharmacology · 2013Article
- Dynamic monitoring of NET activity in mature murine sympathetic terminals using a fluorescent substrate.British journal of pharmacology · 2010Article
- Role of alpha1-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse.British journal of pharmacology · 2008Article
- Alpha1-adrenoceptors are required for normal male sexual function.British journal of pharmacology · 2007Article
- Alpha(2A)-adrenoceptors regulate sympathetic transmitter release in mice kidneys.British journal of pharmacology · 2007Article
- Alpha(1A)-adrenoceptors mediate contractions to phenylephrine in rabbit penile arteries.British journal of pharmacology · 2007Article
- Use of knockout technology to resolve pharmacological problems.British journal of pharmacology · 2007Article
- Role of alpha2A-adrenoceptors in the effects of MDMA on body temperature in the mouse.British journal of pharmacology · 2005Article
- The sources and sequestration of Ca(2+) contributing to neuroeffector Ca(2+) transients in the mouse vas deferens.The Journal of physiology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. The subtypes of alpha(1)- and alpha(2)-adrenoceptor mediating contractions of vas deferens have been examined in wild-type and alpha(2A/D)-adrenoceptor knockout mice. 2. Maximum contractions to noradrenaline but not phenylephrine were significantly greater in vas from wild-type. The alpha(1A)-adrenoceptor antagonist RS100329 (5-methyl-3-[3-[4-[2-(2,2,2,-trifluoroethoxy)phenyl]-1-piperazinyl]propyl]-2,4-(1H)-pyrimidinedione) (10 nM) significantly shifted the potency of noradrenaline. The alpha(2D)-adrenoceptor antagonist BRL 44408 (2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole) significantly reduced the maximum contraction to noradrenaline in wild-type but not in knockout. 3. Following prazosin (0.1 micro M), a component of the contraction to noradrenaline in wild-type but not in knockout was sensitive to the alpha(2)-adrenoceptor antagonist yohimbine. 4. Nifedipine (10 micro M) or suramin (100 micro M) reduced the contraction to 10 Hz stimulation for 4 s to an early peak and small maintained response. The peak was abolished by the alpha(1)-adrenoceptor antagonist prazosin. 5. RS100329 or prazosin inhibited 10 Hz stimulation evoked contractions with a U-shaped concentration-response curve: inhibiting responses up to 0.1 micro M, with a reversal of inhibition above this concentration. In the presence of suramin or nifedipine, the reversal of inhibition by high concentrations of prazosin was reduced. 6. The alpha(1D)-adrenoceptor selective antagonist BMY7378 (8-[2-(4-(2- methoxyphenyl)piperazin-1-yl)ethyl]-8-azaspiro[4,5]decane-7,9-dione) produced inhibition of 10 Hz evoked contractions only in high concentrations. 7. In conclusion, contractions to nerve stimulation in mouse vas deferens involve largely alpha(1A)-adrenoceptors and purinoceptors. alpha(1)-Adrenoceptor antagonists in high concentrations increase the purinergic response presumably by blocking prejunctional alpha(2)-adrenoceptor-mediated inhibition. In the presence of nifedipine, responses are predominantly alpha(1)-adrenoceptor mediated. Contractions to exogenous noradrenaline involved both alpha(1A)- and alpha(2A/D)-adrenoceptors in wild-type mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.